Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hari Gnanasekeram

Cardiovascular Disease Chambersburg, PA Medical Doctor

NPI 1881867018 CMS profile 1185462

3527 Fox Hill Dr, Suite 2001, Chambersburg, PA 17202

Open in the dashboard

General payments

$277,257

971 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hari Gnanasekeram of Chambersburg, PA is reported in the CMS Open Payments database as having received $277,257 across 971 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24 1
2024 General $117 1
2023 General $34,244 168
2022 General $38,579 226
2021 General $70,490 214
2020 General $46,664 115
2019 General $87,140 246

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hari Gnanasekeram
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Hari Gnanasekeram were reported at $24. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Hari Gnanasekeram Cardiovascular Disease median Middle half National median
2019 $87,140 $450 $127–$1,392 $163
2020 $46,664 $242 $77–$751 $114
2021 $70,490 $335 $101–$1,037 $132
2022 $38,579 $395 $121–$1,211 $149
2023 $34,244 $443 $136–$1,283 $160
2024 $117 $450 $136–$1,323 $164
2025 $24 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $113,990 192 payments
  2. Lantheus Medical Imaging, Inc. $48,728 59 payments
  3. AstraZeneca Pharmaceuticals LP $47,580 74 payments
  4. Lilly USA, LLC $17,153 21 payments
  5. Novo Nordisk Inc $16,514 18 payments
  6. Esperion Therapeutics, Inc. $9,363 23 payments
  7. Biotronik Inc. $7,339 58 payments
  8. Janssen Pharmaceuticals, Inc $3,273 135 payments
  9. Boston Scientific Corporation $3,100 12 payments
  10. E.R. Squibb & Sons, L.L.C. $2,282 95 payments
  11. Other $7,934 284 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $211,733 145 payments
  2. Food and Beverage $24,535 721 payments
  3. Consulting Fee $19,600 7 payments
  4. Travel and Lodging $19,366 94 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,000 1 payment
  6. Education $24 3 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $114,005 193 payments
  2. DEFINITY $48,728 59 payments
  3. FARXIGA $46,920 57 payments
  4. JARDIANCE Diabetes $17,119 19 payments
  5. NEXLETOL $9,363 23 payments
  6. NEXLIZET $9,247 16 payments
  7. XARELTO $3,273 135 payments
  8. WATCHMAN $2,864 5 payments
  9. Ozempic $2,435 10 payments
  10. Repatha $1,582 45 payments
  11. Other $12,679 435 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

213

Median for Internal Medicine: 777

Drug cost

$112,016

Median for Internal Medicine: $73,373

Branded share of claims

54.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 47 $41,743
Jardiance Empagliflozin Brand 25 $39,508
Xarelto Rivaroxaban Brand 18 $14,857
Farxiga Dapagliflozin Propanediol Brand 14 $14,716
Metoprolol Succinate Generic 18 $339
Atorvastatin Calcium Generic 18 $268
Losartan Potassium Generic 12 $201
Clopidogrel Clopidogrel Bisulfate Brand 13 $175
Metoprolol Tartrate Generic 27 $122
Furosemide Generic 21 $87

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

971 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record